Results of a Phase II Trial of Neoadjuvant Abiraterone + Prednisone+ Enzalutamide + Leuprolide (APEL) Versus Enzalutamide + Leuprolide (EL) for Patients With High-Risk Localized Prostate Cancer (PC) Undergoing Radical Prostatectomy (RP).
Journal of Clinical Oncology - United States
doi 10.1200/jco.2018.36.6_suppl.79
Full Text
Open PDFAbstract
Available in full text
Date
February 20, 2018
Authors
Publisher
American Society of Clinical Oncology (ASCO)